BiotechTube

LP-300 + Pemetrexed + Carboplatin

Phase 2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenocarcinoma of Lung

Conditions

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Trial Timeline

Mar 1, 2023 → Jun 1, 2026

NCT ID
NCT05456256

About LP-300 + Pemetrexed + Carboplatin

LP-300 + Pemetrexed + Carboplatin is a phase 2 stage product being developed by Lantern Pharma for Adenocarcinoma of Lung. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05456256. Target conditions include Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung.

What happened to similar drugs?

1 of 20 similar drugs in Adenocarcinoma of Lung were approved

Approved (1) Terminated (0) Active (19)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
🔄CT-P16 + AvastinCelltrionPhase 3
🔄Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05456256Phase 2Recruiting

Competing Products

20 competing products in Adenocarcinoma of Lung

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
32
RamucirumabEli LillyPhase 1/2
32
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
BA3182BioAtlaPhase 1
26
Ramucirumab (IMC-1121B ) + PaclitaxelEli LillyPhase 1
29
CT-P16 + AvastinCelltrionPhase 3
40
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
40
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
44
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
42
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
DS-8201aDaiichi SankyoPhase 1
29
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
39
EnzalutamideAstellas PharmaPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44